# Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

> **NCT05488405** · PHASE2 · COMPLETED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 5 (actual)

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **DRUG:** Mesalamine Oral Product

## Key facts

- **NCT ID:** NCT05488405
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-09
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-07-20
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2023-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05488405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05488405, "Mesalazine Oral Suspension in Active Eosinophilic Esophagitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05488405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*